An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists

Among 47,719 adults with type 2 diabetes and ischemic heart disease, 753 received tirzepatide.

• Tirzepatide treatment is associated with a significant reduction in the primary composite outcomes of acute myocardial infarction, ischemic stroke, and all-cause mortality.
• The hazard ratio for these composite outcomes with tirzepatide is 0.60, indicating a potential protective effect.
• Individually, acute myocardial infarction is associated with a hazard ratio of 0.59, suggesting a lower risk compared to GLP-1RA.
• All-cause mortality is associated with a hazard ratio of 0.35 in the tirzepatide group, indicating a reduced risk of death.
• Findings are based on a cohort of adults aged 40 years or older with pre-existing ischemic heart disease and a body mass index of 25 kg/m or higher.

AI simplified